Skip to main content
TipRanks
Go Ultimate75% OFF

Restart Life Sciences (HEAL) AI Stock Analysis

10 Followers
TSE:HEAL

Restart Life Sciences

(CNQX:HEAL)

Select Model
Rating:44Neutral
Price Target:CAD 0.06▼(-3.08% Downside)
Action:upgraded
Date:11/07/26

The score is constrained primarily by severe financial weakness, including no revenue, ongoing losses, and negative operating cash flow. Moderately positive technical momentum provides some support, but the negative P/E and absence of dividend income keep the overall score low.

Positive Factors
Balance Sheet StabilizationPositive equity in 2025 and modest leverage improve financial resilience after earlier stress. This gives Restart more financial flexibility than a persistently overleveraged balance sheet would, although it does not yet establish self-funding or remove the need for disciplined capital management.
Negative Factors
No Recurring RevenueRevenue of zero across 2021–2025 indicates that Restart has not yet demonstrated a durable commercial revenue engine. Without recurring sales, operating costs cannot be supported internally, and future progress remains dependent on achieving commercialization or securing additional funding.

Restart Life Sciences (HEAL) vs. iShares MSCI Canada ETF (EWC)

-50%-40%-30%-20%-10%0%10%20%30%TSE:HEAL-40.91%EWC+20.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 3.96M
Dividend Yield
―
Average Volume (3M)
99.93K
Price to Earnings (P/E)
-1.6
Beta (1Y)
0.08
Revenue Growth
―
EPS Growth
-450.88%
Country
Canada
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Restart Life Sciences Business Overview & Revenue Model

Company Description

Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder,...

Restart Life Sciences Financial Statement Overview

Summary

Financial performance is very weak: the company has no revenue, persistent operating losses, deeply negative operating cash flow, and prior periods of negative equity. Recent positive equity and moderate debt provide limited support.

Income Statement

15Very Negative

Balance Sheet

35Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue465.71K00000
Gross Profit-815.18K0025.41K-3,792-4,998
EBITDA-1.52M-1.34M-656.20K-1.20M-1.84M-2.68M
Net Income-1.50M-1.39M224.75K-1.22M-3.76M-2.68M
Balance Sheet
Total Assets1.90M1.77M190.40K31.06K296.79K881.16K
Cash, Cash Equivalents and Short-Term Investments762.36K1.65M169.95K8,088266.52K218.73K
Total Debt348.35K245.36K79.88K000
Total Liabilities578.90K480.21K489.47K841.66K255.44K422.06K
Stockholders Equity1.32M1.29M-299.07K-810.60K41.34K459.10K
Cash Flow
Free Cash Flow-906.33K-717.22K-71.77K-277.53K-1.44M-1.95M
Operating Cash Flow-906.33K-717.22K-71.77K-277.53K-1.44M-1.95M
Investing Cash Flow-944.52K000029.64K
Financing Cash Flow2.40M2.30M75.00K19.10K1.49M0

Restart Life Sciences Technical Analysis

Technical Analysis SentimentNegative
Last Price0.07

Price Trends

50DMA0.07Negative
100DMA0.08Negative
200DMA0.09Negative

Market Momentum

MACD-0.00Positive
RSI44.08Neutral
STOCH41.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEAL, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.08 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEAL.

Restart Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:HEAL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:HEALTSE:HEAL44NeutralCAD 4.06M-1.59-170.82%――-450.88%

* Healthcare Sector Average

Performance Comparison

0%100%TSE:HEALTSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:HEAL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:HEALRestart Life Sciences Corp.0.07-0.04-35.00%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.10-1.15-92.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026